

# Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

Information for the public

Published: 1 July 2020

[www.nice.org.uk](http://www.nice.org.uk)

Atezolizumab (Tecentriq) with carboplatin and etoposide is available on the NHS as a possible treatment for extensive-stage small-cell lung cancer (ES-SCLC) in adults who have not had treatment for ES-SCLC before. It is only available if you have an Eastern Cooperative Oncology Group status of 0 or 1.

When assessing how having ES-SCLC affects your quality of life, healthcare professionals should take into account any disabilities or difficulties in communicating you might have.

If you are not eligible for atezolizumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Roy Castle Lung Cancer Foundation](#), 0333 323 7200
- [Lung Cancer Nursing UK](#), 01675 477607
- [British Lung Foundation](#), 03000 030 555
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3797-4